{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:37:32Z","timestamp":1785886652154,"version":"3.56.0"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00705-024-06210-4","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:39:54Z","timestamp":1736185194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Next-generation vaccines for influenza B virus: advancements and challenges"],"prefix":"10.1007","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2802-0218","authenticated-orcid":false,"given":"Muhammad Awais","family":"Ashraf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Asif","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azka","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Nabeel","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"6210_CR1","doi-asserted-by":"crossref","unstructured":"Tan J, Arunkumar GA, Krammer F (2018) Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus? Current Opin Immunol 53:45\u201350","DOI":"10.1016\/j.coi.2018.04.002"},{"issue":"4","key":"6210_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/microorganisms8040591","volume":"8","author":"MJ Rivas","year":"2020","unstructured":"Rivas MJ, Alegretti M, C\u00f3ppola L, Ramas V, Chiparelli H, Go\u00f1i N (2020) Epidemiology and genetic variability of circulating influenza B viruses in Uruguay, 2012\u20132019. Microorganisms 8(4):591","journal-title":"Microorganisms"},{"key":"6210_CR3","unstructured":"Wang D Influenza preparedness: lessons learned"},{"issue":"11","key":"6210_CR4","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","volume":"38","author":"N Petrovsky","year":"2015","unstructured":"Petrovsky N (2015) Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug Saf 38(11):1059\u20131074","journal-title":"Drug Saf"},{"issue":"2","key":"6210_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/vaccines3020373","volume":"3","author":"S Sridhar","year":"2015","unstructured":"Sridhar S, Brokstad KA, Cox RJ (2015) Influenza vaccination strategies: comparing inactivated and live attenuated influenza vaccines. Vaccines 3(2):373\u2013389","journal-title":"Vaccines"},{"issue":"7","key":"6210_CR6","doi-asserted-by":"publisher","first-page":"001765","DOI":"10.1099\/jgv.0.001765","volume":"103","author":"JR Shartouny","year":"2022","unstructured":"Shartouny JR, Lowen AC (2022) Message in a bottle: mRNA vaccination for influenza. J Gen Virol 103(7):001765","journal-title":"J Gen Virol"},{"key":"6210_CR7","doi-asserted-by":"crossref","unstructured":"Edler P, Schwab LS, Aban M, Wille M, Spirason N, Deng Y-M et al. (2023) Differential cross-reactivity to the influenza B virus haemagglutinin underpins lineage-specific susceptibility between birth cohorts. bioRxiv. 2023:2023.08. 25.554879.","DOI":"10.1101\/2023.08.25.554879"},{"key":"6210_CR8","doi-asserted-by":"publisher","first-page":"198118","DOI":"10.1016\/j.virusres.2020.198118","volume":"288","author":"W Ma","year":"2020","unstructured":"Ma W (2020) Swine influenza virus: Current status and challenge. Virus Res 288:198118","journal-title":"Virus Res"},{"issue":"1","key":"6210_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/bmb\/ldz036","volume":"132","author":"Y-T Li","year":"2019","unstructured":"Li Y-T, Linster M, Mendenhall IH, Su YC, Smith GJ (2019) Avian influenza viruses in humans: lessons from past outbreaks. Br Med Bull 132(1):81\u201395","journal-title":"Br Med Bull"},{"issue":"9","key":"6210_CR10","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/vaccines9091032","volume":"9","author":"RF Nuwarda","year":"2021","unstructured":"Nuwarda RF, Alharbi AA, Kayser V (2021) An overview of influenza viruses and vaccines. Vaccines 9(9):1032","journal-title":"Vaccines"},{"issue":"9","key":"6210_CR11","doi-asserted-by":"publisher","first-page":"e0222381","DOI":"10.1371\/journal.pone.0222381","volume":"14","author":"S Caini","year":"2019","unstructured":"Caini S, Kusznierz G, Garate VV, Wangchuk S, Thapa B, de Paula J\u00fanior FJ et al (2019) The epidemiological signature of influenza B virus and its B\/Victoria and B\/Yamagata lineages in the 21st century. PLoS ONE 14(9):e0222381","journal-title":"PLoS ONE"},{"key":"6210_CR12","doi-asserted-by":"crossref","unstructured":"Xue L, Zeng G (2019) A comprehensive evaluation on emergency response in China. Springer","DOI":"10.1007\/978-981-13-0644-0"},{"key":"6210_CR13","doi-asserted-by":"publisher","unstructured":"Santos JJ, Finch C, Sutton T, Obadan A, Aguirre I, Wan Z et al (2017) Development of an alternative modified live influenza B virus vaccine. J Virol 91(12). https:\/\/doi.org\/10.1128\/jvi.00056-17","DOI":"10.1128\/jvi.00056-17"},{"issue":"10278","key":"6210_CR14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","volume":"397","author":"OJ Wouters","year":"2021","unstructured":"Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y et al (2021) Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet 397(10278):1023\u20131034","journal-title":"Lancet"},{"issue":"8","key":"6210_CR15","doi-asserted-by":"publisher","first-page":"a038448","DOI":"10.1101\/cshperspect.a038448","volume":"11","author":"M Kanekiyo","year":"2021","unstructured":"Kanekiyo M, Graham BS (2021) Next-generation influenza vaccines. Cold Spring Harbor Perspect Med 11(8):a038448","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"6210_CR16","doi-asserted-by":"publisher","first-page":"1336077","DOI":"10.3389\/fpubh.2024.1336077","volume":"12","author":"D Chen","year":"2024","unstructured":"Chen D, Zhang T, Chen S, Ru X, Shao Q, Ye Q et al (2024) The effect of nonpharmaceutical interventions on influenza virus transmission. Front Public Health 12:1336077","journal-title":"Front Public Health"},{"issue":"1","key":"6210_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrmicro.2017.118","volume":"16","author":"VN Petrova","year":"2018","unstructured":"Petrova VN, Russell CA (2018) The evolution of seasonal influenza viruses. Nat Rev Microbiol 16(1):47\u201360","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"6210_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1073\/pnas.1916585116","volume":"117","author":"RK Virk","year":"2020","unstructured":"Virk RK, Jayakumar J, Mendenhall IH, Moorthy M, Lam P, Linster M et al (2020) Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity. Proc Natl Acad Sci USA 117(1):619\u2013628","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"6210_CR19","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/irv.12969","volume":"16","author":"P Zanobini","year":"2022","unstructured":"Zanobini P, Bonaccorsi G, Lorini C, Haag M, McGovern I, Paget J et al (2022) Global patterns of seasonal influenza activity, duration of activity and virus (sub) type circulation from 2010 to 2020. Influenza Other Respir Viruses 16(4):696\u2013706","journal-title":"Influenza Other Respir Viruses"},{"key":"6210_CR20","doi-asserted-by":"crossref","unstructured":"Caini S, Meijer A, Nunes MC, Henaff L, Zounon M, Boudewijns B et al (2023) Is influenza B\/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases. medRxiv. 2023:2023.09. 25.23296068.","DOI":"10.1101\/2023.09.25.23296068"},{"key":"6210_CR21","doi-asserted-by":"crossref","unstructured":"Treanor JJ (2023) Influenza viruses. Viral infections of humans: epidemiology and control. Springer, pp 1\u201357","DOI":"10.1007\/978-1-4939-9544-8_19-2"},{"issue":"9","key":"6210_CR22","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1080\/21645515.2019.1642056","volume":"15","author":"MA Carlock","year":"2019","unstructured":"Carlock MA, Ingram JG, Clutter EF, Cecil NC, Ramgopal M, Zimmerman RK et al (2019) Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses. Hum Vaccines Immunotherapeutics 15(9):2030\u20132043","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"1","key":"6210_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer R, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB et al (2021) A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med 27(1):106\u2013114","journal-title":"Nat Med"},{"key":"6210_CR24","doi-asserted-by":"crossref","unstructured":"Do THT, Wheatley AK, Kent SJ, Koutsakos M Influenza B virus neuraminidase: a potential target for next-generation vaccines? Expert Rev Vaccines. 2023(just-accepted).","DOI":"10.1080\/14760584.2023.2290691"},{"issue":"2","key":"6210_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41591-018-0340-z","volume":"25","author":"S Yamayoshi","year":"2019","unstructured":"Yamayoshi S, Kawaoka Y (2019) Current and future influenza vaccines. Nat Med 25(2):212\u2013220","journal-title":"Nat Med"},{"key":"6210_CR26","unstructured":"Cottrell CA (2020) Structure-based HIV immunogen design. The Scripps research Institute"},{"issue":"45","key":"6210_CR27","doi-asserted-by":"publisher","first-page":"6573","DOI":"10.1016\/j.vaccine.2021.08.010","volume":"39","author":"KA Moore","year":"2021","unstructured":"Moore KA, Ostrowsky JT, Kraigsley AM, Mehr AJ, Bresee JS, Friede MH et al (2021) A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future. Vaccine 39(45):6573\u20136584","journal-title":"Vaccine"},{"issue":"Supplement4","key":"6210_CR28","doi-asserted-by":"publisher","first-page":"S405","DOI":"10.1093\/infdis\/jiab269","volume":"224","author":"T Becker","year":"2021","unstructured":"Becker T, Elbahesh H, Reperant LA, Rimmelzwaan GF, Osterhaus AD (2021) Influenza vaccines: successes and continuing challenges. J Infect Dis 224(Supplement4):S405\u2013S19","journal-title":"J Infect Dis"},{"issue":"4","key":"6210_CR29","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/vaccines8040574","volume":"8","author":"EE Sayedahmed","year":"2020","unstructured":"Sayedahmed EE, Elkashif A, Alhashimi M, Sambhara S, Mittal SK (2020) Adenoviral vector-based vaccine platforms for developing the next generation of influenza vaccines. Vaccines 8(4):574","journal-title":"Vaccines"},{"issue":"11","key":"6210_CR30","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.3390\/microorganisms8111745","volume":"8","author":"S Rockman","year":"2020","unstructured":"Rockman S, Laurie KL, Parkes S, Wheatley A, Barr IG (2020) New technologies for influenza vaccines. Microorganisms 8(11):1745","journal-title":"Microorganisms"},{"issue":"7","key":"6210_CR31","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1080\/21645515.2017.1313375","volume":"13","author":"R Ray","year":"2017","unstructured":"Ray R, Dos Santos G, Buck PO, Claeys C, Matias G, Innis BL et al (2017) A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Hum Vaccines Immunotherapeutics 13(7):1640\u20131652","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"1","key":"6210_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12976-017-0074-5","volume":"15","author":"A Alessa","year":"2018","unstructured":"Alessa A, Faezipour M (2018) A review of influenza detection and prediction through social networking sites. Theoretical Biology Med Modelling 15(1):1\u201327","journal-title":"Theoretical Biology Med Modelling"},{"issue":"11","key":"6210_CR33","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2217\/fmb-2019-0340","volume":"15","author":"L Hensen","year":"2020","unstructured":"Hensen L, Kedzierska K, Koutsakos M (2020) Innate and adaptive immunity toward influenza B viruses. Future Microbiol 15(11):1045\u20131058","journal-title":"Future Microbiol"},{"issue":"1","key":"6210_CR34","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41467-020-14579-4","volume":"11","author":"S Boyoglu-Barnum","year":"2020","unstructured":"Boyoglu-Barnum S, Hutchinson GB, Boyington JC, Moin SM, Gillespie RA, Tsybovsky Y et al (2020) Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses. Nat Commun 11(1):791","journal-title":"Nat Commun"},{"issue":"8","key":"6210_CR35","doi-asserted-by":"publisher","first-page":"02134","DOI":"10.1128\/jvi","volume":"93","author":"SR Christensen","year":"2019","unstructured":"Christensen SR, Toulmin SA, Griesman T, Lamerato LE, Petrie JG, Martin ET et al (2019) Assessing the protective potential of H1N1 influenza virus hemagglutinin head and stalk antibodies in humans. J Virol 93(8). https:\/\/doi.org\/10.1128\/jvi.02134-18","journal-title":"J Virol"},{"issue":"9","key":"6210_CR36","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","volume":"21","author":"G Pantaleo","year":"2022","unstructured":"Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L (2022) Antibodies to combat viral infections: development strategies and progress. Nat Rev Drug Discovery 21(9):676\u2013696","journal-title":"Nat Rev Drug Discovery"},{"issue":"7","key":"6210_CR37","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1002\/bit.27355","volume":"117","author":"YS Kim","year":"2020","unstructured":"Kim YS, Lim J, Sung J, Cheong Y, Lee EY, Kim J et al (2020) Built-in RNA\u2010mediated chaperone (chaperna) for antigen folding tailored to immunized hosts. Biotechnol Bioeng 117(7):1990\u20132007","journal-title":"Biotechnol Bioeng"},{"issue":"9","key":"6210_CR38","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/imcb.12284","volume":"97","author":"TJ Hayman","year":"2019","unstructured":"Hayman TJ, Hsu AC, Kolesnik TB, Dagley LF, Willemsen J, Tate MD et al (2019) RIPLET, and not TRIM25, is required for endogenous RIG-I\u2010dependent antiviral responses. Immunol Cell Biol 97(9):840\u2013852","journal-title":"Immunol Cell Biol"},{"issue":"6","key":"6210_CR39","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1128\/JVI.02477-07","volume":"82","author":"Q Wang","year":"2008","unstructured":"Wang Q, Cheng F, Lu M, Tian X, Ma J (2008) Crystal structure of unliganded influenza B virus hemagglutinin. J Virol 82(6):3011\u20133020","journal-title":"J Virol"},{"issue":"2","key":"6210_CR40","doi-asserted-by":"publisher","first-page":"01673","DOI":"10.1128\/jvi","volume":"93","author":"W Sun","year":"2019","unstructured":"Sun W, Kang DS, Zheng A, Liu ST, Broecker F, Simon V et al (2019) Antibody responses toward the major antigenic sites of influenza B virus hemagglutinin in mice, ferrets, and humans. J Virol 93(2). https:\/\/doi.org\/10.1128\/jvi.01673-18","journal-title":"J Virol"},{"issue":"6","key":"6210_CR41","doi-asserted-by":"publisher","first-page":"01696","DOI":"10.1128\/jvi","volume":"93","author":"G Asthagiri Arunkumar","year":"2019","unstructured":"Asthagiri Arunkumar G, Ioannou A, Wohlbold TJ, Meade P, Aslam S, Amanat F et al (2019) Broadly cross-reactive, nonneutralizing antibodies against influenza B virus hemagglutinin demonstrate effector function-dependent protection against lethal viral challenge in mice. J Virol 93(6). https:\/\/doi.org\/10.1128\/jvi.01696-18","journal-title":"J Virol"},{"issue":"7","key":"6210_CR42","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/08820139.2021.1909617","volume":"50","author":"JM Bartley","year":"2021","unstructured":"Bartley JM, Cadar AN, Martin DE (2021) Better, faster, stronger: mRNA vaccines show promise for influenza vaccination in older adults. Immunol Investig 50(7):810\u2013820","journal-title":"Immunol Investig"},{"issue":"1","key":"6210_CR43","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/14760584.2023.2266033","volume":"22","author":"RA Tripp","year":"2023","unstructured":"Tripp RA (2023) Understanding immunity to influenza: implications for future vaccine development. Expert Rev Vaccines 22(1):871\u2013875","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"6210_CR44","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1080\/08820139.2021.1903033","volume":"50","author":"W Luo","year":"2021","unstructured":"Luo W, Yin Q (2021) B cell response to vaccination. Immunol Investig 50(7):780\u2013801","journal-title":"Immunol Investig"},{"issue":"1","key":"6210_CR45","doi-asserted-by":"publisher","first-page":"14234","DOI":"10.1038\/ncomms14234","volume":"8","author":"N Chai","year":"2017","unstructured":"Chai N, Swem LR, Park S, Nakamura G, Chiang N, Estevez A et al (2017) A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun 8(1):14234","journal-title":"Nat Commun"},{"issue":"5","key":"6210_CR46","doi-asserted-by":"publisher","first-page":"02269","DOI":"10.1128\/aac","volume":"62","author":"A Vigil","year":"2018","unstructured":"Vigil A, Est\u00e9lles A, Kauvar LM, Johnson SK, Tripp RA, Wittekind M (2018) Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses. Antimicrob Agents Chemother 62(5). https:\/\/doi.org\/10.1128\/aac.02269-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"6210_CR47","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41564-017-0011-8","volume":"2","author":"TJ Wohlbold","year":"2017","unstructured":"Wohlbold TJ, Podolsky KA, Chromikova V, Kirkpatrick E, Falconieri V, Meade P et al (2017) Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes. Nat Microbiol 2(10):1415\u20131424","journal-title":"Nat Microbiol"},{"issue":"2","key":"6210_CR48","doi-asserted-by":"publisher","first-page":"e1003150","DOI":"10.1371\/journal.ppat.1003150","volume":"9","author":"M Yasugi","year":"2013","unstructured":"Yasugi M, Kubota-Koketsu R, Yamashita A, Kawashita N, Du A, Sasaki T et al (2013) Human monoclonal antibodies broadly neutralizing against influenza B virus. PLoS Pathog 9(2):e1003150","journal-title":"PLoS Pathog"},{"issue":"412","key":"6210_CR49","doi-asserted-by":"publisher","first-page":"eaam5752","DOI":"10.1126\/scitranslmed.aam5752","volume":"9","author":"C Shen","year":"2017","unstructured":"Shen C, Chen J, Li R, Zhang M, Wang G, Stegalkina S et al (2017) A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci Transl Med 9(412):eaam5752","journal-title":"Sci Transl Med"},{"issue":"2","key":"6210_CR50","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/v11020190","volume":"11","author":"P Blanco-Lobo","year":"2019","unstructured":"Blanco-Lobo P, Nogales A, Rodr\u00edguez L, Mart\u00ednez-Sobrido L (2019) Novel approaches for the development of live attenuated influenza vaccines. Viruses 11(2):190","journal-title":"Viruses"},{"key":"6210_CR51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.coviro.2020.10.005","volume":"44","author":"S Cardenas-Garcia","year":"2020","unstructured":"Cardenas-Garcia S, Caceres CJ, Rajao D, Perez DR (2020) Reverse genetics for influenza B viruses and recent advances in vaccine development. Curr Opin Virol 44:191\u2013202","journal-title":"Curr Opin Virol"},{"issue":"16","key":"6210_CR52","doi-asserted-by":"publisher","first-page":"8804","DOI":"10.1073\/pnas.96.16.8804","volume":"96","author":"A Pekosz","year":"1999","unstructured":"Pekosz A, He B, Lamb RA (1999) Reverse genetics of negative-strand RNA viruses: closing the circle. Proc Natl Acad Sci USA 96(16):8804\u20138806","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"6210_CR53","doi-asserted-by":"publisher","first-page":"11744","DOI":"10.1128\/JVI.76.22.11744-11747.2002","volume":"76","author":"D Jackson","year":"2002","unstructured":"Jackson D, Cadman A, Zurcher T, Barclay WS (2002) A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA. J Virol 76(22):11744\u201311747","journal-title":"J Virol"},{"key":"6210_CR54","doi-asserted-by":"crossref","unstructured":"Nogales A, Perez DR, Santos J, Finch C, Mart\u00ednez-Sobrido L (2017) Reverse genetics of influenza B viruses. Reverse Genetics of RNA Viruses: Methods and Protocols, pp 205\u2013\u200938","DOI":"10.1007\/978-1-4939-6964-7_14"},{"key":"6210_CR55","doi-asserted-by":"crossref","unstructured":"Hoffmann E, Mahmood K, Yang C-F, Webster RG, Greenberg HB, Kemble G (2002) Rescue of influenza B virus from eight plasmids. Proc Nat Acad Sci 99(17):11411-6","DOI":"10.1073\/pnas.172393399"},{"issue":"1","key":"6210_CR56","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/v11010006","volume":"11","author":"C Fage","year":"2018","unstructured":"Fage C, Abed Y, Checkmahomed L, Venable M-C, Boivin G (2018) In vitro properties and virulence of contemporary recombinant influenza B viruses harboring mutations of cross-resistance to neuraminidase inhibitors. Viruses 11(1):6","journal-title":"Viruses"},{"key":"6210_CR57","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.3389\/fmicb.2019.02862","volume":"10","author":"A Nogales","year":"2019","unstructured":"Nogales A, Aydillo T, \u00c1vila-P\u00e9rez G, Escalera A, Chiem K, Cadagan R et al (2019) Functional Characterization and Direct Comparison of Influenza A, B, C, and D NS1 Proteins in vitro and in vivo. Front Microbiol 10:2862","journal-title":"Front Microbiol"},{"issue":"23","key":"6210_CR58","doi-asserted-by":"publisher","first-page":"12226","DOI":"10.1128\/JVI.02164-15","volume":"89","author":"BO Fulton","year":"2015","unstructured":"Fulton BO, Palese P, Heaton NS (2015) Replication-competent influenza B reporter viruses as tools for screening antivirals and antibodies. J Virol 89(23):12226\u201312231","journal-title":"J Virol"},{"issue":"1","key":"6210_CR59","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41467-019-08617-z","volume":"10","author":"RE Dumm","year":"2019","unstructured":"Dumm RE, Fiege JK, Waring BM, Kuo CT, Langlois RA, Heaton NS (2019) Non-lytic clearance of influenza B virus from infected cells preserves epithelial barrier function. Nat Commun 10(1):779","journal-title":"Nat Commun"},{"key":"6210_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.virusres.2015.11.014","volume":"213","author":"A Nogales","year":"2016","unstructured":"Nogales A, Rodr\u00edguez-S\u00e1nchez I, Monte K, Lenschow DJ, Perez DR, Mart\u00ednez-Sobrido L (2016) Replication-competent fluorescent-expressing influenza B virus. Virus Res 213:69\u201381","journal-title":"Virus Res"},{"issue":"8","key":"6210_CR61","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/v11080736","volume":"11","author":"RE Dumm","year":"2019","unstructured":"Dumm RE, Heaton NS (2019) The development and use of reporter influenza B viruses. Viruses 11(8):736","journal-title":"Viruses"},{"issue":"1","key":"6210_CR62","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/vaccines9010065","volume":"9","author":"MD Buschmann","year":"2021","unstructured":"Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D (2021) Nanomaterial delivery systems for mRNA vaccines. Vaccines 9(1):65","journal-title":"Vaccines"},{"key":"6210_CR63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","volume":"41","author":"KJ Ewer","year":"2016","unstructured":"Ewer KJ, Lambe T, Rollier CS, Spencer AJ, Hill AV, Dorrell L (2016) Viral vectors as vaccine platforms: from immunogenicity to impact. Curr Opin Immunol 41:47\u201354","journal-title":"Curr Opin Immunol"},{"key":"6210_CR64","doi-asserted-by":"crossref","unstructured":"Woolsey C, Borisevich V, Fears AC, Agans KN, Deer DJ, Prasad AN et al (2023) Recombinant vesicular stomatitis virus\u2013vectored vaccine induces long-lasting immunity against Nipah virus disease. J Clin Investig 133(3)","DOI":"10.1172\/JCI164946"},{"key":"6210_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40794-020-0101-0","volume":"6","author":"LH Chen","year":"2020","unstructured":"Chen LH, Wilson ME (2020) Yellow fever control: current epidemiology and vaccination strategies. Trop Dis travel Med vaccines 6:1\u201310","journal-title":"Trop Dis travel Med vaccines"},{"issue":"2","key":"6210_CR66","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/vaccines7020053","volume":"7","author":"E Kotey","year":"2019","unstructured":"Kotey E, Lukosaityte D, Quaye O, Ampofo W, Awandare G, Iqbal M (2019) Current and novel approaches in influenza management. Vaccines 7(2):53","journal-title":"Vaccines"},{"issue":"1","key":"6210_CR67","doi-asserted-by":"publisher","first-page":"e00414","DOI":"10.1128\/CVI.00414-16","volume":"24","author":"DF Hoft","year":"2017","unstructured":"Hoft DF, Lottenbach KR, Blazevic A, Turan A, Blevins TP, Pacatte TP et al (2017) Comparisons of the humoral and cellular immune responses induced by live attenuated influenza vaccine and inactivated influenza vaccine in adults. Clin Vaccine Immunol 24(1):e00414\u2013e00416","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"6210_CR68","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2009.02.006","volume":"30","author":"PG Thomas","year":"2009","unstructured":"Thomas PG, Dash P, Aldridge JR, Ellebedy AH, Reynolds C, Funk AJ et al (2009) The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30(4):566\u2013575","journal-title":"Immunity"},{"issue":"42","key":"6210_CR69","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1016\/j.vaccine.2012.07.031","volume":"30","author":"P Tennis","year":"2012","unstructured":"Tennis P, Toback SL, Andrews EB, McQuay LJ, Ambrose CS (2012) A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009\u20132010 season. Vaccine 30(42):6099\u20136102","journal-title":"Vaccine"},{"issue":"11","key":"6210_CR70","doi-asserted-by":"publisher","first-page":"e49941","DOI":"10.1371\/journal.pone.0049941","volume":"7","author":"S Sarntivijai","year":"2012","unstructured":"Sarntivijai S, Xiang Z, Shedden KA, Markel H, Omenn GS, Athey BD et al (2012) Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines. PLoS ONE 7(11):e49941","journal-title":"PLoS ONE"},{"issue":"14","key":"6210_CR71","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.vaccine.2013.01.055","volume":"31","author":"SL Toback","year":"2013","unstructured":"Toback SL, Ambrose CS, Eaton A, Hansen J, Aukes L, Lewis N et al (2013) A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24\u201359 months of age. Vaccine 31(14):1812\u20131818","journal-title":"Vaccine"},{"issue":"5","key":"6210_CR72","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/biot.201400438","volume":"10","author":"RS Felberbaum","year":"2015","unstructured":"Felberbaum RS (2015) The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotechnol J 10(5):702\u2013714","journal-title":"Biotechnol J"},{"key":"6210_CR73","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejpb.2015.05.023","volume":"94","author":"PC Soema","year":"2015","unstructured":"Soema PC, Kompier R, Amorij J-P, Kersten GF (2015) Current and next generation influenza vaccines: Formulation and production strategies. Eur J Pharm Biopharm 94:251\u2013263","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"6210_CR74","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/nbt.2666","volume":"31","author":"RA Langlois","year":"2013","unstructured":"Langlois RA, Albrecht RA, Kimble B, Sutton T, Shapiro JS, Finch C et al (2013) MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. Nat Biotechnol 31(9):844\u2013847","journal-title":"Nat Biotechnol"},{"key":"6210_CR75","first-page":"423","volume-title":"Influenza vaccines and vaccination strategies","author":"KM Neuzil","year":"2016","unstructured":"Neuzil KM, Ortiz JR (2016) Influenza vaccines and vaccination strategies. Elsevier, The Vaccine Book, pp 423\u2013444"},{"issue":"6","key":"6210_CR76","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.3390\/v7062770","volume":"7","author":"HS Chahar","year":"2015","unstructured":"Chahar HS, Bao X, Casola A (2015) Exosomes and their role in the life cycle and pathogenesis of RNA viruses. Viruses 7(6):3204\u20133225","journal-title":"Viruses"},{"issue":"9","key":"6210_CR77","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.3390\/v7092862","volume":"7","author":"M Alenquer","year":"2015","unstructured":"Alenquer M, Amorim MJ (2015) Exosome biogenesis, regulation, and function in viral infection. Viruses 7(9):5066\u20135083","journal-title":"Viruses"},{"issue":"1","key":"6210_CR78","doi-asserted-by":"publisher","first-page":"23743","DOI":"10.3402\/jev.v3.23743","volume":"3","author":"L Cheng","year":"2014","unstructured":"Cheng L, Sharples RA, Scicluna BJ, Hill AF (2014) Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicle 3(1):23743","journal-title":"J Extracell Vesicle"},{"key":"6210_CR79","doi-asserted-by":"crossref","unstructured":"Salido-Guadarrama I, Romero-Cordoba S, Peralta-Zaragoza O, Hidalgo-Miranda A, Rodriguez-Dorantes M (2014) MicroRNAs transported by exosomes in body fluids as mediators of intercellular communication in cancer. OTT, pp 1327\u20131338","DOI":"10.2147\/OTT.S61562"},{"issue":"10","key":"6210_CR80","doi-asserted-by":"publisher","first-page":"e76811","DOI":"10.1371\/journal.pone.0076811","volume":"8","author":"PA Tambyah","year":"2013","unstructured":"Tambyah PA, Sepramaniam S, Mohamed Ali J, Chai SC, Swaminathan P, Armugam A et al (2013) microRNAs in circulation are altered in response to influenza A virus infection in humans. PLoS ONE 8(10):e76811","journal-title":"PLoS ONE"},{"issue":"11","key":"6210_CR81","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/jcp.25738","volume":"232","author":"B Rashidi","year":"2017","unstructured":"Rashidi B, Hoseini Z, Sahebkar A, Mirzaei H (2017) Anti-atherosclerotic effects of vitamins D and E in suppression of atherogenesis. J Cell Physiol 232(11):2968\u20132976","journal-title":"J Cell Physiol"},{"key":"6210_CR82","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.biopha.2017.01.161","volume":"89","author":"B Rashidi","year":"2017","unstructured":"Rashidi B, Malekzadeh M, Goodarzi M, Masoudifar A, Mirzaei H (2017) Green tea and its anti-angiogenesis effects. Biomed Pharmacother 89:949\u2013956","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"6210_CR83","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1002\/jcp.27214","volume":"234","author":"E Iranifar","year":"2019","unstructured":"Iranifar E, Seresht BM, Momeni F, Fadaei E, Mehr MH, Ebrahimi Z et al (2019) Exosomes and microRNAs: new potential therapeutic candidates in Alzheimer disease therapy. J Cell Physiol 234(3):2296\u20132305","journal-title":"J Cell Physiol"},{"issue":"5","key":"6210_CR84","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1002\/jcb.26599","volume":"119","author":"J Tavakolizadeh","year":"2018","unstructured":"Tavakolizadeh J, Roshanaei K, Salmaninejad A, Yari R, Nahand JS, Sarkarizi HK et al (2018) MicroRNAs and exosomes in depression: potential diagnostic biomarkers. J Cell Biochem 119(5):3783\u20133797","journal-title":"J Cell Biochem"},{"key":"6210_CR85","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijid.2015.07.002","volume":"38","author":"C Feng","year":"2015","unstructured":"Feng C, Tan M, Sun W, Shi Y, Xing Z (2015) Attenuation of the influenza virus by microRNA response element in vivo and protective efficacy against 2009 pandemic H1N1 virus in mice. Int J Infect Dis 38:146\u2013152","journal-title":"Int J Infect Dis"},{"issue":"37","key":"6210_CR86","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1016\/j.vaccine.2018.07.065","volume":"36","author":"M Shinjoh","year":"2018","unstructured":"Shinjoh M, Sugaya N, Yamaguchi Y, Iibuchi N, Kamimaki I, Goto A et al (2018) Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016\/17 season. Vaccine 36(37):5510\u20135518","journal-title":"Vaccine"},{"issue":"12","key":"6210_CR87","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1093\/aje\/kwy145","volume":"187","author":"SL Epstein","year":"2018","unstructured":"Epstein SL (2018) Universal influenza vaccines: progress in achieving broad cross-protection in vivo. Am J Epidemiol 187(12):2603\u20132614","journal-title":"Am J Epidemiol"},{"key":"6210_CR88","doi-asserted-by":"crossref","unstructured":"Casasnovas JM (2013) Virus-receptor interactions and receptor-mediated virus entry into host cells. Structure and physics of viruses: an integrated textbook, pp 441\u2013\u200966","DOI":"10.1007\/978-94-007-6552-8_15"},{"issue":"1\u20132","key":"6210_CR89","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.virusres.2006.09.013","volume":"124","author":"S Boulo","year":"2007","unstructured":"Boulo S, Akarsu H, Ruigrok RW, Baudin F (2007) Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. Virus Res 124(1\u20132):12\u201321","journal-title":"Virus Res"},{"issue":"1","key":"6210_CR90","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.virol.2012.06.016","volume":"432","author":"A Wanitchang","year":"2012","unstructured":"Wanitchang A, Narkpuk J, Jaru-ampornpan P, Jengarn J, Jongkaewwattana A (2012) Inhibition of influenza A virus replication by influenza B virus nucleoprotein: an insight into interference between influenza A and B viruses. Virology 432(1):194\u2013203","journal-title":"Virology"},{"issue":"1","key":"6210_CR91","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1146\/annurev.bi.52.070183.002343","volume":"52","author":"RA Lamb","year":"1983","unstructured":"Lamb RA, Choppin PW (1983) The gene structure and replication of influenza virus. Annu Rev Biochem 52(1):467\u2013506","journal-title":"Annu Rev Biochem"},{"issue":"9","key":"6210_CR92","doi-asserted-by":"publisher","first-page":"e1008583","DOI":"10.1371\/journal.ppat.1008583","volume":"16","author":"C Viboud","year":"2020","unstructured":"Viboud C, Gostic K, Nelson MI, Price GE, Perofsky A, Sun K et al (2020) Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine. PLoS Pathog 16(9):e1008583","journal-title":"PLoS Pathog"},{"key":"6210_CR93","first-page":"100076","volume":"6","author":"M Hellerstein","year":"2020","unstructured":"Hellerstein M (2020) What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? Vaccine: X 6:100076","journal-title":"Vaccine: X"},{"issue":"1","key":"6210_CR94","doi-asserted-by":"publisher","first-page":"02298","DOI":"10.1128\/mbio","volume":"8","author":"N Nao","year":"2017","unstructured":"Nao N, Yamagishi J, Miyamoto H, Igarashi M, Manzoor R, Ohnuma A et al (2017) Genetic predisposition to acquire a polybasic cleavage site for highly pathogenic avian influenza virus hemagglutinin. MBio 8(1). https:\/\/doi.org\/10.1128\/mbio.02298-16","journal-title":"MBio"},{"key":"6210_CR95","doi-asserted-by":"crossref","unstructured":"Raymond DD, Bajic G, Ferdman J, Suphaphiphat P, Settembre EC, Moody MA et al (2018) Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. Proc Nat Acad Sci 115(1):168\u2013\u200973","DOI":"10.1073\/pnas.1715471115"},{"issue":"3","key":"6210_CR96","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3390\/vaccines9030257","volume":"9","author":"BL Bullard","year":"2021","unstructured":"Bullard BL, Weaver EA (2021) Strategies targeting hemagglutinin as a universal influenza vaccine. Vaccines 9(3):257","journal-title":"Vaccines"},{"issue":"1","key":"6210_CR97","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41541-021-00403-7","volume":"6","author":"AB Arunachalam","year":"2021","unstructured":"Arunachalam AB, Post P, Rudin D (2021) Unique features of a recombinant haemagglutinin influenza vaccine that influence vaccine performance. npj Vaccines 6(1):144","journal-title":"npj Vaccines"},{"issue":"6373","key":"6210_CR98","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1126\/science.aan8806","volume":"359","author":"Y Du","year":"2018","unstructured":"Du Y, Xin L, Shi Y, Zhang T-H, Wu NC, Dai L et al (2018) Genome-wide identification of interferon-sensitive mutations enables influenza vaccine design. Science 359(6373):290\u2013296","journal-title":"Science"},{"key":"6210_CR99","doi-asserted-by":"publisher","unstructured":"Fulton BO, Sun W, Heaton NS, Palese P (2018) The influenza B virus hemagglutinin head domain is less tolerant to transposon mutagenesis than that of the influenza A virus. J Virol 92(16). https:\/\/doi.org\/10.1128\/jvi.00754-18","DOI":"10.1128\/jvi.00754-18"},{"issue":"2","key":"6210_CR100","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1089\/vim.2017.0129","volume":"31","author":"MO Altman","year":"2018","unstructured":"Altman MO, Angeletti D, Yewdell JW (2018) Antibody immunodominance: the key to understanding influenza virus antigenic drift. Viral Immunol 31(2):142\u2013149","journal-title":"Viral Immunol"},{"issue":"1","key":"6210_CR101","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/s41467-018-03665-3","volume":"9","author":"MB Doud","year":"2018","unstructured":"Doud MB, Lee JM, Bloom JD (2018) How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin. Nat Commun 9(1):1386","journal-title":"Nat Commun"},{"issue":"7","key":"6210_CR102","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/v13071278","volume":"13","author":"CL White","year":"2021","unstructured":"White CL, Chiem K, Perez DR, Santos J, Cardenas Garcia S, Nogales A et al (2021) A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines. Viruses 13(7):1278","journal-title":"Viruses"},{"key":"6210_CR103","doi-asserted-by":"crossref","unstructured":"Grohskopf LA (2019) Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2019\u201320 influenza season. MMWR Recommendations Rep 68","DOI":"10.15585\/mmwr.rr6803a1"},{"key":"6210_CR104","doi-asserted-by":"crossref","unstructured":"Bhangde S, Lodaya RN, Amiji MM (2023) Nanoscale vaccines for influenza. Nanomedicines for the prevention and treatment of infectious diseases. Springer, pp 331\u2013347","DOI":"10.1007\/978-3-031-39020-3_11"},{"key":"6210_CR105","doi-asserted-by":"publisher","first-page":"878943","DOI":"10.3389\/fimmu.2022.878943","volume":"13","author":"MB Carascal","year":"2022","unstructured":"Carascal MB, Pavon RDN, Rivera WL (2022) Recent progress in recombinant influenza vaccine development toward heterosubtypic immune response. Front Immunol 13:878943","journal-title":"Front Immunol"},{"issue":"5","key":"6210_CR106","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/cid\/ciab152","volume":"73","author":"C Boikos","year":"2021","unstructured":"Boikos C, Fischer L, O\u2019Brien D, Vasey J, Sylvester GC, Mansi JA (2021) Relative effectiveness of adjuvanted trivalent inactivated influenza vaccine versus egg-derived quadrivalent inactivated influenza vaccines and high-dose trivalent influenza vaccine in preventing influenza-related medical encounters in US adults\u2009\u2265\u200965 years during the 2017\u20132018 and 2018\u20132019 influenza seasons. Clin Infect Dis 73(5):816\u2013823","journal-title":"Clin Infect Dis"},{"issue":"6","key":"6210_CR107","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/irv.12871","volume":"15","author":"BL Coleman","year":"2021","unstructured":"Coleman BL, Sanderson R, Haag MD, McGovern I (2021) Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta\u2010analysis. Influenza Other Respir Viruses 15(6):813\u2013823","journal-title":"Influenza Other Respir Viruses"},{"issue":"8","key":"6210_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6908a1","volume":"69","author":"LA Grohskopf","year":"2020","unstructured":"Grohskopf LA, Alyanak E, Broder KR, Blanton LH, Fry AM, Jernigan DB et al (2020) Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2020\u201321 influenza season. MMWR Recommendations Rep 69(8):1","journal-title":"MMWR Recommendations Rep"},{"key":"6210_CR109","unstructured":"Accessed on January 23. https:\/\/www.cdcgov\/flu\/prevent\/keyfactshtm#Flu-Vaccine-Options (2024)"},{"key":"6210_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-021-00772-0","volume":"19","author":"V Lampinen","year":"2021","unstructured":"Lampinen V, Heinim\u00e4ki S, Laitinen OH, Pesu M, Hankaniemi MM, Blazevic V et al (2021) Modular vaccine platform based on the norovirus-like particle. J Nanobiotechnol 19:1\u201314","journal-title":"J Nanobiotechnol"},{"key":"6210_CR111","first-page":"100036","volume":"2","author":"DC Jenkin","year":"2019","unstructured":"Jenkin DC, Mahgoub H, Morales KF, Lambach P, Nguyen-Van-Tam JS (2019) A rapid evidence appraisal of influenza vaccination in health workers: An important policy in an area of imperfect evidence. Vaccine: X 2:100036","journal-title":"Vaccine: X"},{"key":"6210_CR112","doi-asserted-by":"publisher","first-page":"583077","DOI":"10.3389\/fimmu.2020.583077","volume":"11","author":"M Brisse","year":"2020","unstructured":"Brisse M, Vrba SM, Kirk N, Liang Y, Ly H (2020) Emerging concepts and technologies in vaccine development. Front Immunol 11:583077","journal-title":"Front Immunol"},{"issue":"3","key":"6210_CR113","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/vaccines6030037","volume":"6","author":"MO Mohsen","year":"2018","unstructured":"Mohsen MO, Gomes AC, Vogel M, Bachmann MF (2018) Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system. Vaccines 6(3):37","journal-title":"Vaccines"},{"issue":"10","key":"6210_CR114","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S2215-0366(19)30289-5","volume":"6","author":"M-C Lai","year":"2019","unstructured":"Lai M-C, Kassee C, Besney R, Bonato S, Hull L, Mandy W et al (2019) Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. Lancet Psychiatry 6(10):819\u2013829","journal-title":"Lancet Psychiatry"},{"issue":"10181","key":"6210_CR115","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","volume":"393","author":"C Villanueva","year":"2019","unstructured":"Villanueva C, Albillos A, Genesc\u00e0 J, Garcia-Pagan JC, Calleja JL, Aracil C et al (2019) \u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. lancet 393(10181):1597\u20131608","journal-title":"lancet"},{"issue":"46","key":"6210_CR116","doi-asserted-by":"publisher","first-page":"6857","DOI":"10.1016\/j.vaccine.2019.09.057","volume":"37","author":"S Buffin","year":"2019","unstructured":"Buffin S, Peubez I, Barri\u00e8re F, Nicola\u00ef M-C, Tapia T, Dhir V et al (2019) Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies. Vaccine 37(46):6857\u20136867","journal-title":"Vaccine"},{"issue":"D1","key":"6210_CR117","doi-asserted-by":"publisher","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","volume":"47","author":"S Kim","year":"2019","unstructured":"Kim S, Chen J, Cheng T, Gindulyte A, He J, He S et al (2019) PubChem 2019 update: improved access to chemical data. Nucleic Acids Res 47(D1):D1102\u2013D9","journal-title":"Nucleic Acids Res"},{"key":"6210_CR118","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s15010-020-01555-9","volume":"49","author":"S Schumacher","year":"2021","unstructured":"Schumacher S, Salmanton-Garc\u00eda J, Cornely OA, Mellinghoff SC (2021) Increasing influenza vaccination coverage in healthcare workers: a review on campaign strategies and their effect. Infection 49:387\u2013399","journal-title":"Infection"},{"issue":"10","key":"6210_CR119","doi-asserted-by":"publisher","first-page":"e1264","DOI":"10.1016\/S2214-109X(20)30308-9","volume":"8","author":"K Abbas","year":"2020","unstructured":"Abbas K, Procter SR, van Zandvoort K, Clark A, Funk S, Mengistu T et al (2020) Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit\u2013risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. Lancet Global Health 8(10):e1264\u2013e72","journal-title":"Lancet Global Health"},{"issue":"Supplement1","key":"6210_CR120","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1093\/infdis\/jiz024","volume":"219","author":"JR Ortiz","year":"2019","unstructured":"Ortiz JR, Neuzil KM (2019) Influenza immunization in low-and middle-income countries: preparing for next-generation influenza vaccines. J Infect Dis 219(Supplement1):S97\u2013S106","journal-title":"J Infect Dis"},{"issue":"1","key":"6210_CR121","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S1473-3099(19)30393-7","volume":"20","author":"DI Bernstein","year":"2020","unstructured":"Bernstein DI, Guptill J, Naficy A, Nachbagauer R, Berlanda-Scorza F, Feser J et al (2020) Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infect Dis 20(1):80\u201391","journal-title":"Lancet Infect Dis"},{"key":"6210_CR122","doi-asserted-by":"publisher","unstructured":"Skarlupka AL, Bebin-Blackwell A-G, Sumner SF, Ross TM (2021) Universal influenza virus neuraminidase vaccine elicits protective immune responses against human seasonal and pre-pandemic strains. J Virol 95(17). https:\/\/doi.org\/10.1128\/jvi.00759-21","DOI":"10.1128\/jvi.00759-21"},{"issue":"11","key":"6210_CR123","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-2600(19)30199-7","volume":"7","author":"JH Beigel","year":"2019","unstructured":"Beigel JH, Aga E, Elie-Turenne M-C, Cho J, Tebas P, Clark CL et al (2019) Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respiratory Med 7(11):941\u2013950","journal-title":"Lancet Respiratory Med"},{"issue":"3","key":"6210_CR124","doi-asserted-by":"publisher","first-page":"e2179","DOI":"10.1002\/rmv.2179","volume":"31","author":"A Pormohammad","year":"2021","unstructured":"Pormohammad A, Ghorbani S, Khatami A, Razizadeh MH, Alborzi E, Zarei M et al (2021) Comparison of influenza type A and B with COVID-19: A global systematic review and meta\u2010analysis on clinical, laboratory and radiographic findings. Rev Med Virol 31(3):e2179","journal-title":"Rev Med Virol"},{"issue":"40","key":"6210_CR125","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.1016\/j.vaccine.2019.08.028","volume":"37","author":"SM Raj","year":"2019","unstructured":"Raj SM, Chughtai AA, Sharma A, Tan TC, MacIntyre CR (2019) Cost-benefit analysis of a national influenza vaccination program in preventing hospitalisation costs in Australian adults aged 50\u201364 years old. Vaccine 37(40):5979\u20135985","journal-title":"Vaccine"},{"issue":"41","key":"6210_CR126","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.1016\/j.vaccine.2023.08.031","volume":"41","author":"NR Waterlow","year":"2023","unstructured":"Waterlow NR, Procter SR, van Leeuwen E, Radhakrishnan S, Jit M, Eggo RM (2023) The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis. Vaccine 41(41):6017\u20136024","journal-title":"Vaccine"},{"key":"6210_CR127","doi-asserted-by":"crossref","unstructured":"Al-Yaman F (2017) The Australian Burden of Disease Study: impact and causes of illness and death in Aboriginal and Torres Strait Islander people, 2011. Public Health Res Pract 27(4)","DOI":"10.17061\/phrp2741732"},{"issue":"2","key":"6210_CR128","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4161\/hv.18433","volume":"8","author":"R Jimenez-Garcia","year":"2012","unstructured":"Jimenez-Garcia R, Her\u0144ndez-Barrera V, Rodr\u00edguez-Rieiro C, de Andr\u00e9s AL, Miguel-Diez Jd, Trujillo IJ et al (2012) Are age-based strategies effective in increasing influenza vaccination coverage? the Spanish experience. Hum Vaccines Immunotherapeutics 8(2):228\u2013233","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"6210_CR129","doi-asserted-by":"crossref","unstructured":"Cheng AC, Holmes M, Dwyer DE, Senanayake S, Cooley L, Irving LB et al (2019) Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN)","DOI":"10.33321\/cdi.2019.43.39"},{"issue":"3","key":"6210_CR130","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/irv.12446","volume":"11","author":"P Koszalka","year":"2017","unstructured":"Koszalka P, Tilmanis D, Hurt AC (2017) Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses 11(3):240\u2013246","journal-title":"Influenza Other Respir Viruses"},{"key":"6210_CR131","doi-asserted-by":"crossref","unstructured":"Webster RG (1999) Antigenic variation in influenza viruses. In: Origin and evolution of viruses. Elsevier, pp 377\u201390","DOI":"10.1016\/B978-012220360-2\/50015-5"},{"key":"6210_CR132","doi-asserted-by":"crossref","unstructured":"Caini S, Meijer A, Nunes MC, Henaff L, Zounon M, Boudewijns B et al (2024) Probable extinction of influenza B\/Yamagata and its public health implications: a systematic literature review and assessment of global surveillance databases. Lancet Microbe","DOI":"10.1101\/2023.09.25.23296068"},{"issue":"5","key":"6210_CR133","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","volume":"82","author":"N Petrovsky","year":"2004","unstructured":"Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82(5):488\u2013496","journal-title":"Immunol Cell Biol"},{"issue":"4","key":"6210_CR134","doi-asserted-by":"publisher","first-page":"e1089","DOI":"10.1542\/peds.2013-2377","volume":"132","author":"CI Diseases","year":"2013","unstructured":"Diseases CI, Brady MT, Byington CL, Davies HD, Edwards KM, Jackson MA et al (2013) Recommendations for prevention and control of influenza in children, 2013\u20132014. Pediatrics 132(4):e1089\u2013e104","journal-title":"Pediatrics"},{"key":"6210_CR135","doi-asserted-by":"crossref","unstructured":"Maldonado YA, Zaoutis TE, Banerjee R, Barnett ED, Campbell JD, Caserta MT et al (2019) Recommendations for prevention and control of influenza in children, 2019\u20132020. Pediatrics 144(4)","DOI":"10.1542\/peds.2019-2478"},{"issue":"1","key":"6210_CR136","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejor.2018.01.015","volume":"268","author":"LE Duijzer","year":"2018","unstructured":"Duijzer LE, Van Jaarsveld W, Dekker R (2018) Literature review: The vaccine supply chain. Eur J Oper Res 268(1):174\u2013192","journal-title":"Eur J Oper Res"},{"issue":"16","key":"6210_CR137","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","volume":"39","author":"SS Rosa","year":"2021","unstructured":"Rosa SS, Prazeres DM, Azevedo AM, Marques MP (2021) mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine 39(16):2190\u20132200","journal-title":"Vaccine"},{"issue":"2","key":"6210_CR138","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10288-018-0395-1","volume":"17","author":"S Lemmens","year":"2019","unstructured":"Lemmens S (2019) The trade-off between inventories, lead time and capacity: application to vaccine supply chain design. 4OR 17(2):223\u2013224","journal-title":"4OR"},{"issue":"3","key":"6210_CR139","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.vaccine.2020.12.018","volume":"39","author":"E Sparrow","year":"2021","unstructured":"Sparrow E, Wood JG, Chadwick C, Newall AT, Torvaldsen S, Moen A et al (2021) Global production capacity of seasonal and pandemic influenza vaccines in 2019. Vaccine 39(3):512\u2013520","journal-title":"Vaccine"},{"key":"6210_CR140","doi-asserted-by":"publisher","first-page":"251513552090812","DOI":"10.1177\/2515135520908121","volume":"8","author":"S Rajaram","year":"2020","unstructured":"Rajaram S, Boikos C, Gelone DK, Gandhi A (2020) Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Therapeutic Adv vaccines immunotherapy 8:2515135520908121","journal-title":"Therapeutic Adv vaccines immunotherapy"},{"key":"6210_CR141","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fcimb.2019.00107","volume":"9","author":"AC Sherman","year":"2019","unstructured":"Sherman AC, Mehta A, Dickert NW, Anderson EJ, Rouphael N (2019) The future of flu: a review of the human challenge model and systems biology for advancement of influenza vaccinology. Front Cell Infect Microbiol 9:107","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"6210_CR142","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ejor.2019.11.025","volume":"283","author":"S Enayati","year":"2020","unstructured":"Enayati S, \u00d6zalt\u0131n OY (2020) Optimal influenza vaccine distribution with equity. Eur J Oper Res 283(2):714\u2013725","journal-title":"Eur J Oper Res"},{"issue":"1","key":"6210_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-020-0626-6","volume":"27","author":"J-R Chen","year":"2020","unstructured":"Chen J-R, Liu Y-M, Tseng Y-C, Ma C (2020) Better influenza vaccines: an industry perspective. J Biomed Sci 27(1):1\u201311","journal-title":"J Biomed Sci"},{"issue":"Supplement1","key":"6210_CR144","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1093\/infdis\/jiy745","volume":"219","author":"M Kanekiyo","year":"2019","unstructured":"Kanekiyo M, Ellis D, King NP (2019) New vaccine design and delivery technologies. J Infect Dis 219(Supplement1):S88\u2013S96","journal-title":"J Infect Dis"},{"key":"6210_CR145","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.cherd.2016.02.015","volume":"109","author":"S Lemmens","year":"2016","unstructured":"Lemmens S, Decouttere C, Vandaele N, Bernuzzi M (2016) A review of integrated supply chain network design models: Key issues for vaccine supply chains. Chem Eng Res Des 109:366\u2013384","journal-title":"Chem Eng Res Des"},{"key":"6210_CR146","doi-asserted-by":"publisher","first-page":"608852","DOI":"10.3389\/fpubh.2020.608852","volume":"8","author":"SR Hursh","year":"2020","unstructured":"Hursh SR, Strickland JC, Schwartz LP, Reed DD (2020) Quantifying the impact of public perceptions on vaccine acceptance using behavioral economics. Front public health 8:608852","journal-title":"Front public health"},{"key":"6210_CR147","doi-asserted-by":"crossref","unstructured":"Parmet WE, Paul J (2020) COVID-19: the first posttruth pandemic. American Public Health Association, pp 945\u2013946","DOI":"10.2105\/AJPH.2020.305721"},{"key":"6210_CR148","unstructured":"Lobelo EE (2018) A cost-effectiveness analysis of influenza vaccination. Low-Income 18\u201364 Year Olds in the United States. Tulane University, School of Public Health and Tropical Medicine"},{"issue":"27","key":"6210_CR149","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1016\/j.vaccine.2018.05.057","volume":"36","author":"WC Putri","year":"2018","unstructured":"Putri WC, Muscatello DJ, Stockwell MS, Newall AT (2018) Economic burden of seasonal influenza in the United States. Vaccine 36(27):3960\u20133966","journal-title":"Vaccine"},{"issue":"7","key":"6210_CR150","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/apm.13141","volume":"129","author":"S \u00d8rskov","year":"2021","unstructured":"\u00d8rskov S, Nielsen BF, F\u00f8ns S, Sneppen K, Simonsen L (2021) The COVID-19 pandemic: key considerations for the epidemic and its control. Apmis 129(7):408\u2013420","journal-title":"Apmis"},{"issue":"10","key":"6210_CR151","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/M13-2071","volume":"160","author":"N Khazeni","year":"2014","unstructured":"Khazeni N, Hutton DW, Collins CI, Garber AM, Owens DK (2014) Health and economic benefits of early vaccination and nonpharmaceutical interventions for a human influenza A (H7N9) pandemic: a modeling study. Ann Intern Med 160(10):684\u2013694","journal-title":"Ann Intern Med"},{"key":"6210_CR152","doi-asserted-by":"crossref","unstructured":"Carrico J, La EM, Talbird SE, Chen Y-T, Nyaku MK, Carias C et al (2022) Value of the immunization program for children in the 2017 US birth cohort. Pediatrics 150(3)","DOI":"10.1542\/peds.2021-056007"},{"key":"6210_CR153","volume-title":"Health at a Glance: Asia\/Pacific 2020 Measuring Progress Towards Universal Health Coverage: Measuring Progress Towards Universal","author":"WH Organization","year":"2020","unstructured":"Organization WH (2020) Health at a Glance: Asia\/Pacific 2020 measuring progress towards universal health coverage: measuring progress towards universal. oecd Publishing, Health Coverage"},{"issue":"6","key":"6210_CR154","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jpeds.2005.06.031","volume":"147","author":"JL Hall","year":"2005","unstructured":"Hall JL, Katz BZ (2005) Cost of influenza hospitalization at a tertiary care children's hospital and its impact on the cost-benefit analysis of the recommendation for universal influenza immunization in children age 6 to 23 months. J Pediatr 147(6):807\u2013811","journal-title":"J Pediatr"},{"key":"6210_CR155","doi-asserted-by":"crossref","unstructured":"Walsh JA, Maher C (2011) Economic implications of influenza and influenza vaccine. Influenza Vaccines for the Future, pp 425\u201340","DOI":"10.1007\/978-3-0346-0279-2_19"},{"issue":"3","key":"6210_CR156","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1728-4457.2007.00179.x","volume":"33","author":"L MacKellar","year":"2007","unstructured":"MacKellar L (2007) Pandemic influenza: a review. Popul Dev Rev 33(3):429\u2013451","journal-title":"Popul Dev Rev"},{"issue":"4","key":"6210_CR157","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/irv.12558","volume":"12","author":"MJ Meijboom","year":"2018","unstructured":"Meijboom MJ, Riphagen-Dalhuisen J, Hak E (2018) The potential economic value of influenza vaccination for healthcare workers in The Netherlands. Influenza Other Respir Viruses 12(4):457\u2013464","journal-title":"Influenza Other Respir Viruses"},{"issue":"40","key":"6210_CR158","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.1016\/j.vaccine.2017.08.034","volume":"35","author":"K Sano","year":"2017","unstructured":"Sano K, Ainai A, Suzuki T, Hasegawa H (2017) The road to a more effective influenza vaccine: Up to date studies and future prospects. Vaccine 35(40):5388\u20135395","journal-title":"Vaccine"},{"issue":"4","key":"6210_CR159","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/su10041232","volume":"10","author":"Y Liu","year":"2018","unstructured":"Liu Y, Cheng Y, Yan Z, Ye X (2018) Multilevel analysis of international scientific collaboration network in the influenza virus vaccine field: 2006\u20132013. Sustainability 10(4):1232","journal-title":"Sustainability"},{"issue":"1","key":"6210_CR160","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1021\/acsnano.6b07343","volume":"11","author":"KT Gause","year":"2017","unstructured":"Gause KT, Wheatley AK, Cui J, Yan Y, Kent SJ, Caruso F (2017) Immunological principles guiding the rational design of particles for vaccine delivery. ACS Nano 11(1):54\u201368","journal-title":"ACS Nano"},{"issue":"6","key":"6210_CR161","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/vaccines9060579","volume":"9","author":"M Van Tilbeurgh","year":"2021","unstructured":"Van Tilbeurgh M, Lemdani K, Beignon A-S, Chapon C, Tchitchek N, Cheraitia L et al (2021) Predictive markers of immunogenicity and efficacy for human vaccines. Vaccines 9(6):579","journal-title":"Vaccines"},{"issue":"1","key":"6210_CR162","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41590-017-0007-9","volume":"19","author":"BS Graham","year":"2018","unstructured":"Graham BS, Sullivan NJ (2018) Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic. Nat Immunol 19(1):20\u201328","journal-title":"Nat Immunol"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-024-06210-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-024-06210-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-024-06210-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T03:24:19Z","timestamp":1738898659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-024-06210-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":162,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6210"],"URL":"https:\/\/doi.org\/10.1007\/s00705-024-06210-4","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"25"}}